Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gilead Sciences' cell therapy Kite Pharma has ... Xanthopoulos said the deal will "potentially accelerate Shoreline's timeline to the clinic, expand our pipeline opportunities and deliver ...

S&P 500 E-Mini futures are trending down -1.08% this morning as investors digest key U.S. inflation data and also await further testimony from Federal Reserve Chair Jerome P ...

A spokesperson for Advanz told pharmaphorum that, at the moment, the company does not have a timeline for when a ... Another potential option is Gilead Sciences PPAR agonist Livdelzi (seladelpar ...

Real-time index price for TSX Diversified Banks EW Index (TXDE), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

The stock's fall snapped a three-day winning streak.

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.